Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients

NCT01638247

Last updated date
Study Location
Kliniken Essen-Mitte
Essen, Nordrhein-Westfalen, 45136, Germany
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Male Breast Cancer
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-85 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Written informed consent for all study procedures.

2. Complete baseline documentation sent to GBG Forschungs GmbH.

3. Male patients.

4. Age ≥ 18 years.

5. Karnofsky-Index ≥ 60%.

6. Histologically confirmed unilateral or bilateral carcinoma or of the breast at primary diagnosis (enrolment possible in neoadjuvant, adjuvant and metastatic situation).

7: No target lesion necessary for metastatic situation 8. Positive hormone receptor status (e.g. ER and/or PR-receptor positive). 9. Completed staging prior randomisation ( within 8 weeks after diagnose or last therapy (operation, chemotherapy or radiation), minimum: chest X-ray, ultrasound of the liver, bone scan).

In case of positive findings, further investigations are required to verify the findings as clinically indicated.

10. Prior chemotherapy is possible. In case of adjuvant treatment: adequate surgical treatment with histological complete resection including axillary lymph nodes if patients are included as adjuvant treatment. A sentinel lymph node biopsy is possible if the sentinel is not involved.

11. Normal cardiac function must be confirmed by ECG within three months prior to randomisation.

12. Laboratory requirements (≤ 14 days before therapy start): Hematology

- Hemoglobin ≥ 9 g/dL,

- Leukocytes 4 - 10 x1000/µL,

- Thrombocytes 150 - 400 x1000/µL. Hepatic function

- ASAT (SGOT) or ALAT (SGPT) ≤ 2x UNL,

- Total bilirubin ≤ 2x UNL. Renal function

- Serum creatinine ≤ 1.5x UNL,

- Creatinine clearance > 30 mL/min (if creatinine is above UNL, according to Cockroft-Gault).

- Cholesterol 200 - 240 mg/dL (5.18 - 6.22 mmol/L),

- HDL cholesterol > 40 mg/dL (> 1 mmol/L),

- LDL cholesterol ≤ 160 mg/dL (≤ 4 mmol/L).

- Prostate specific antigen (PSA) ≤ 2.5 ng/mL. 13. Two serum samples (5 mL) centrally made available. 14. Paraffin tumor tissue block and full blood sample centrally made available (except when the patient does not agree to central biomaterial collection).

15. The patient must be accessible for treatment. Patients can simultaneously be registered in the register study of the University Hospital of Magdeburg.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Female patients.


2. Prior endocrine therapy of breast carcinoma.


3. Known or suspected hypersensitivity reaction to the compounds or incorporated
substances.


4. No indication for endocrine treatment.


5. Life expectancy of less than six months.


6. International Prostate Symptom Score (IPSS) > 17.


7. Current diagnosis of a Prostate carcinoma.


8. History of prostate cancer within the last five years and regardless the time frame
all patients with hormone receptor positive prostate carcinoma who have received
endocrine treatment.


9. Concurrent neuronal or cardiac disease, poorly controlled arterial hypertension.


10. Previous thromboembolic event within the last five years (except from thromboembolic
events correlated to implanted devices (e.g. port thrombosis)


11. Currently active hepatitis.


12. Disease significantly affecting gastrointestinal function, e.g. malabsorption
syndrome, resection of the stomach or small bowel.


13. Concurrent treatment with other experimental drugs or participation in another
clinical trial with any investigational, not marketed drug within 30 days prior to
study entry.


14. Patients who are not able to give informed consent as defined according to AMG.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Male Breast CancerTamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
NCT01638247
  1. Essen, Nordrhein-Westfalen
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Official Title  ICMJE A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Brief Summary A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (MALE).
Detailed Description

Breast cancer in men is a rare disease with approximately 0.5- 1% of all breast cancer cases. Each year, about 400 to 450 cases are diagnosed in Germany. Men tend to present with more advanced disease than women, probably due to the lack of awareness of male breast cancer from both, the patient and the physicians.

Therefore, at presentation they usually have lump or nipple inversion, and more than 40% of the patients have a stage III or IV disease. The great majority of patients have an invasive ductal (90%), hormone receptor positive (90%), HER2 negative (90%) tumor.

The only available information on adjuvant therapies derives from few retrospective cases and retrospective studies with a little number of cases. Therefore, treatment strategies are not based on data from prospective, randomised clinical studies, and optimal treatment is unknown. As a result, current clinical management is generally extrapolated from principles established for the treatment of female breast carcinoma. As the majority of male breast cancer patients have a hormone receptor positive tumor, they receive tamoxifen 20 mg for five years as standard endocrine adjuvant therapy. A lot of withdrawals from the treatment were documented in male breast cancer due to side-effects under tamoxifen therapy. Furthermore, the clinical outcome of tamoxifen-treated male breast cancer patients may be influenced by the activity of cytochrome P450 2D6 enzymes that catalyse the formation of anti-estrogenic metabolites endoxifen and 4-hydroxy-tamoxifen. Therefore a significant proportion of poor to moderate metaboliser is proposed to do not benefit from adjuvant tamoxifen therapy.

Although women benefit from adjuvant treatment with aromatase inhibitors (AI) regarding disease-free-survival, overall survival and treatment toxicity, only case reports of men treated with AI exist. Other data show, that under AI, there is only a suppression of estradiol of about 40-50% with an increase of testosterone of about 50%. Among men on AIs, it is possible that the hypothalamic-pituitary feedback loop results in an increase substrate for aromatisation, and thus prevents complete estrogen suppression.

However, an optimal suppression (80%) of the peripheral estradiol level would be a necessary condition for a therapeutic benefit of AI in men with breast cancer.

By adding a gonadotropin-releasing hormone analogue, the negative feedback loop would be interrupted and complete estrogen suppression may be achieved.

In conclusion, there is a great lack on information for the treatment of male patients with breast cancer.

Prospective multi-centre, randomised trials in men with breast cancer are necessary in order to prove the effect of tamoxifen + GnRH analogue versus none and versus AI + GnRH analogue as adjuvant or neoadjuvant endocrine treatment.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Male Breast Cancer
Intervention  ICMJE
  • Drug: Tamoxifen
    25 mg daily.
  • Drug: Tamoxifen and GnRH analogue

    25 mg Tamoxifen daily and GnRH analogue:

    • Goserelin (10.8 mg s.c. after randomisation and after three months) or
    • Leuprorelin (11.25 mg s.c. after randomisation and after three months).
    Other Name: TRENATONE, ZOLADEX
  • Drug: Exemestane and GnRH analogue

    25 mg Exemestane daily and GnRH analogue:

    • Goserelin (10.8 mg s.c. after randomisation and after three months) or
    • Leuprorelin (11.25 mg s.c. after randomisation and after three months).
    Other Name: AROMASIN, TRENATONE, ZOLADEX.
Study Arms  ICMJE
  • Active Comparator: Tamoxifen
    Tamoxifen alone (daily).
    Intervention: Drug: Tamoxifen
  • Experimental: Tamoxifen and GnRH analogue
    Tamoxifen (daily) + GnRH analogue (at randomisation and after three months).
    Intervention: Drug: Tamoxifen and GnRH analogue
  • Experimental: Exemestane and GnRH analogue
    Exemestane (daily) + GnRH analogue (at randomisation and after three months).
    Intervention: Drug: Exemestane and GnRH analogue
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 25, 2017)
56
Original Estimated Enrollment  ICMJE
 (submitted: July 10, 2012)
48
Actual Study Completion Date  ICMJE May 2018
Actual Primary Completion Date May 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria

  1. Written informed consent for all study procedures.
  2. Complete baseline documentation sent to GBG Forschungs GmbH.
  3. Male patients.
  4. Age ? 18 years.
  5. Karnofsky-Index ? 60%.
  6. Histologically confirmed unilateral or bilateral carcinoma or of the breast at primary diagnosis (enrolment possible in neoadjuvant, adjuvant and metastatic situation).

7: No target lesion necessary for metastatic situation 8. Positive hormone receptor status (e.g. ER and/or PR-receptor positive). 9. Completed staging prior randomisation ( within 8 weeks after diagnose or last therapy (operation, chemotherapy or radiation), minimum: chest X-ray, ultrasound of the liver, bone scan).

In case of positive findings, further investigations are required to verify the findings as clinically indicated.

10. Prior chemotherapy is possible. In case of adjuvant treatment: adequate surgical treatment with histological complete resection including axillary lymph nodes if patients are included as adjuvant treatment. A sentinel lymph node biopsy is possible if the sentinel is not involved.

11. Normal cardiac function must be confirmed by ECG within three months prior to randomisation.

12. Laboratory requirements (? 14 days before therapy start): Hematology

  • Hemoglobin ? 9 g/dL,
  • Leukocytes 4 - 10 x1000/µL,
  • Thrombocytes 150 - 400 x1000/µL. Hepatic function
  • ASAT (SGOT) or ALAT (SGPT) ? 2x UNL,
  • Total bilirubin ? 2x UNL. Renal function
  • Serum creatinine ? 1.5x UNL,
  • Creatinine clearance > 30 mL/min (if creatinine is above UNL, according to Cockroft-Gault).
  • Cholesterol 200 - 240 mg/dL (5.18 - 6.22 mmol/L),
  • HDL cholesterol > 40 mg/dL (> 1 mmol/L),
  • LDL cholesterol ? 160 mg/dL (? 4 mmol/L).
  • Prostate specific antigen (PSA) ? 2.5 ng/mL. 13. Two serum samples (5 mL) centrally made available. 14. Paraffin tumor tissue block and full blood sample centrally made available (except when the patient does not agree to central biomaterial collection).

    15. The patient must be accessible for treatment. Patients can simultaneously be registered in the register study of the University Hospital of Magdeburg.

Exclusion Criteria

  1. Female patients.
  2. Prior endocrine therapy of breast carcinoma.
  3. Known or suspected hypersensitivity reaction to the compounds or incorporated substances.
  4. No indication for endocrine treatment.
  5. Life expectancy of less than six months.
  6. International Prostate Symptom Score (IPSS) > 17.
  7. Current diagnosis of a Prostate carcinoma.
  8. History of prostate cancer within the last five years and regardless the time frame all patients with hormone receptor positive prostate carcinoma who have received endocrine treatment.
  9. Concurrent neuronal or cardiac disease, poorly controlled arterial hypertension.
  10. Previous thromboembolic event within the last five years (except from thromboembolic events correlated to implanted devices (e.g. port thrombosis)
  11. Currently active hepatitis.
  12. Disease significantly affecting gastrointestinal function, e.g. malabsorption syndrome, resection of the stomach or small bowel.
  13. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry.
  14. Patients who are not able to give informed consent as defined according to AMG.
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 18 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01638247
Other Study ID Numbers  ICMJE GBG 54
2009-015122-11 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party German Breast Group
Study Sponsor  ICMJE German Breast Group
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Mattea Reinisch, MDKliniken Essen-Mitte
PRS Account German Breast Group
Verification Date September 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP